Detalhe da pesquisa
1.
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
MMWR Morb Mortal Wkly Rep
; 71(11): 422-428, 2022 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35298453
2.
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(9): 352-358, 2022 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35239634
3.
Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents.
Pediatrics
; 151(5)2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37026401
4.
School-Based Influenza Vaccination: Health and Economic Impact of Maine's 2009 Influenza Vaccination Program.
Health Serv Res
; 52 Suppl 2: 2307-2330, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29130266